Research development on pharmacokinetics and therapeutic drug monitoring of dasatinib
LUO Xing-xian
HUANG Lin
ZHAO Hai-yan
XUE Xue-cai
HU Lei
YANG Chang-qing
FENG Wan-yu
Abstract：Tyrosine kinase inhibitors (TKIS) play an important role in tumor cell proliferation and apoptosis, and are commonly used in treatment of cancers including chronic myeloid leukemia, gastrointestinal stromal tumors and non-cell lung cancer diseases with high selectivity and fewer adverse effects. As a second-generation oral broadspectrum tyrosine kinase inhibitor, Dasatinib are widely used in chronic leukemia patients resistance or intolerance of methanesulfonic acid imatinib by inhibiting BCR-ABL, SRC family, C-Kit, PDGF-B and other tyrosine kinases.With the increase in clinical application, the efficacy and adverse reactions of dasatinib have gradually emerged.Based on the literatures of recent years, this paper reviews the drug mechanism, pharmacokinetic characteristics, drug safety and therapeutic drug monitoring of dasatinib so as to provide references for the personalized and rational drug use of dasatinib.
Keywords：dasatinibchronic myelogenous leukemiatyrosine kinase inhibitorspharmacokineticstherapeutic drug monitoring
Publication Date：2018-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 1737-1743 )